Ming-sheng Huang

600 Tianhe Road
Guangzhou, 510630, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Journal: Hepatology (Baltimore, Md.)

Published: July 13, 2025

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Journal: Journal of cachexia, sarcopenia and muscle

Published: March 14, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

The causal effect of gut microbiota on hepatic encephalopathy: a mendelian randomization analysis.

The causal effect of gut microbiota on hepatic encephalopathy: a mendelian randomization analysis.

Journal: BMC medical genomics

Published: October 12, 2023

Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.

Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.

Journal: Journal of gastrointestinal oncology

Published: June 07, 2023

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy.

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy.

Journal: World journal of gastroenterology

Published: March 03, 2023

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Journal: Signal transduction and targeted therapy

Published: June 14, 2022

Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.

Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.

Journal: Neoplasma

Published: August 17, 2021

DNA N6-methyladenine involvement and regulation of hepatocellular carcinoma development.

DNA N6-methyladenine involvement and regulation of hepatocellular carcinoma development.

Journal: Genomics

Published: June 30, 2021

Aspirin-induced long-term tumor remission in hepatocellular carcinoma with adenomatous polyposis coli stop-gain mutation: A case report.

Aspirin-induced long-term tumor remission in hepatocellular carcinoma with adenomatous polyposis coli stop-gain mutation: A case report.

Journal: World journal of clinical cases

Published: February 01, 2021

Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis.

Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis.

Journal: American journal of translational research

Published: August 05, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026